Does Acamprosate Cause Weight Gain?
Acamprosate is associated with weight gain as a documented adverse effect, occurring frequently (≥1% of patients) in clinical trials, though the magnitude is typically modest and must be weighed against its proven efficacy in maintaining alcohol abstinence.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for acamprosate explicitly lists weight gain as a "frequent" adverse event under Metabolic and Nutritional Disorders (occurring in at least 1/100 patients) 1. This classification places weight gain among the more commonly observed side effects, though the exact incidence rate and magnitude are not specified in the labeling.
Importantly, the FDA label also notes that patients taking acamprosate concomitantly with antidepressants more commonly reported both weight gain AND weight loss compared to those taking either medication alone 1. This suggests the weight effect may be bidirectional and influenced by concurrent medications.
Clinical Trial Data
In one small trial examining acamprosate for binge eating disorder (off-label use), weight and BMI decreased slightly in the acamprosate group but increased in the placebo group among treatment completers 2. However, this was a 10-week trial in a different patient population (binge eating disorder rather than alcohol use disorder), limiting direct applicability.
Clinical Context and Practical Considerations
Key Points for Clinical Decision-Making:
The weight gain risk should NOT deter prescribing acamprosate when indicated for alcohol use disorder, as acamprosate is the only intervention with high-quality evidence supporting its efficacy in maintaining abstinence in detoxified alcohol-dependent patients 3
Monitor weight at baseline and periodically during treatment, particularly in:
- Patients taking concurrent antidepressants (bidirectional weight changes more common) 1
- Unemployed or younger patients (higher susceptibility to medication-related weight changes based on antipsychotic literature patterns)
The magnitude of weight gain is typically modest and occurs less frequently than gastrointestinal side effects (diarrhea occurs in 10-17% of patients) 1
Common Pitfall to Avoid:
Do not withhold acamprosate due to weight gain concerns in patients who need pharmacotherapy for alcohol use disorder. The mortality and morbidity benefits of maintaining alcohol abstinence far outweigh the risk of modest weight gain. Acamprosate has demonstrated superiority over placebo in maintaining abstinence with moderate-quality evidence 3.
When Weight Gain Occurs:
- Implement standard weight management strategies (dietary counseling, physical activity)
- Consider whether concurrent medications (especially antidepressants) may be contributing 1
- Reassess the risk-benefit ratio only if weight gain is substantial (≥7% baseline weight) and causing significant health complications
- Do not discontinue acamprosate without ensuring alternative alcohol use disorder treatment is in place